Veradigm delisted to OTC as cash tumbles 59% amid SEC probe
Healthcare IT company projects flat revenue for 2025 while grappling with regulatory scrutiny
Veradigm, the healthcare technology provider formerly known as Allscripts, has been delisted from the NASDAQ and shifted to over-the-counter trading after revealing a 59% plunge in its cash position and projecting flat revenue growth for fiscal 2025.
The company's cash reserves have dwindled to $120 million from $294 million, primarily driven by debt repayments, according to a recent regulatory filing. The depletion comes as Veradigm faces dual headwinds: an ongoing SEC investigation and a pending securities class action lawsuit.
Fiscal 2025 revenue is projected at $584 to $589 million, essentially flat to down 1% compared with the prior year. That outlook starkly contrasts with an analyst estimate of $146 million that the company dismissed as misleading. For the trailing twelve months, Veradigm recorded $588 million in revenue.
The company's shares, which traded as high as $11.80 within the past year, have fallen sharply as the delisting removes access to major institutional investors that typically avoid OTC markets. The stock currently trades around $4.74, giving the Chicago-based company a market capitalization of approximately $527 million.
Veradigm's leadership has been in turmoil throughout 2024. The company terminated former chief executive Richard Poulton and chief financial officer Leah Jones in December 2023. Dr. Yin Ho served as interim CEO until June 2024, when Tom Langan, previously president and chief commercial officer, assumed the interim role. Veradigm has indicated it does not plan to make permanent executive appointments while exploring strategic alternatives, including a potential sale or merger.
The company's financial metrics reflect significant strain. Veradigm reported a negative 14.7% profit margin and earnings per share of -$0.18 for the trailing twelve months. Despite generating $308 million in gross profit over that period, operational challenges have translated to negative returns on both assets and equity.
Institutional investors still hold approximately 42% of shares outstanding, a figure that may decline following the OTC delisting as many funds have mandates restricting ownership of unlisted securities. The company's 108.6 million shares outstanding include roughly 81 million in public float.
Amid the crisis, Veradigm's leadership has outlined what it calls a "Reset, Recover, Reignite" strategy targeting a 2026 recovery. The three-pronged approach aims to stabilize operations, address regulatory concerns, and rebuild growth momentum. However, analysts at major firms have expressed skepticism, noting that the company's severely constrained cash position limits its ability to invest in necessary turnaround initiatives.
The SEC investigation, which has not been publicly detailed, adds another layer of uncertainty. Regulatory scrutiny in the healthcare technology sector has intensified following several high-profile cases involving data privacy and revenue recognition practices.
For the broader healthcare IT industry, Veradigm's struggles highlight the competitive pressures facing companies that fail to innovate rapidly. The sector has seen consolidation as larger players acquire smaller firms with specialized technology platforms, while standalone companies like Veradigm struggle to achieve scale.
With 41.9% institutional ownership remaining, some investors appear to be maintaining positions despite the delisting. However, the lack of access to NASDAQ's trading infrastructure and reduced visibility among retail investors could accelerate selling pressure in the coming months.
The company's debt repayment, while improving its balance sheet leverage, has left it with minimal financial flexibility to weather operational challenges or pursue strategic opportunities. As Veradigm executes its recovery strategy, investors will be watching closely for any signs of stabilization in cash burn rates and progress in resolving the regulatory overhang that continues to shadow the stock.